New Targets for the Treatment of Hypertension and Associated Diseases

New Targets for the Treatment of Hypertension and Associated Diseases,Volume 94 in the Advances in Pharmacology serial, highlights new advances in the field, with this new volume presenting interesting chapters on Cytochrome P450, 20-hydroxyeicosatetraenoic acid and GPR75 pathway in hypertension, Treatment of hypertension with soluble epoxide hydrolase inhibitors, Effects of allosteric modifiers of adenosine receptors in the heart, Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury, Drugs affecting the nitric oxide- cyclic GMP pathway in hypertension, Relaxin-2 and Serelaxin in renal and cardiac dysfunction in hypertension, and more.

Format: Hardback
Length: 312 pages
Publication date: 10 June 2022
Publisher: Elsevier Science & Technology

New Targets for the Treatment of Hypertension and Associated Diseases,Volume 94 in the Advances in Pharmacology serial, presents new advances in the field, with this new volume presenting interesting chapters on Cytochrome P450, 20-hydroxyeicosatetraenoic acid and GPR75 pathway in hypertension, Treatment of hypertension with soluble epoxide hydrolase inhibitors, Effects of allosteric modifiers of adenosine receptors in the heart, Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury, Drugs affecting the nitric oxide- cyclic GMP pathway in hypertension, Relaxin-2 and Serelaxin in renal and cardiac dysfunction in hypertension, and more.

Hypertension is a common condition that affects millions of people worldwide. It is characterized by high blood pressure, which can lead to serious health problems such as heart disease, stroke, and kidney failure. While there are many treatments available for hypertension, there is still a need for new and more effective therapies.

In recent years, researchers have made significant progress in understanding the mechanisms underlying hypertension and developing new treatments. One area of focus has been on the role of the cytochrome P450, 20-hydroxyeicosatetraenoic acid (20-HETE) and GPR75 pathway in hypertension.

20-HETE is a lipid molecule that is produced by the body and has been implicated in the development of hypertension. Studies have shown that high levels of 20-HETE can cause blood vessels to constrict, leading to high blood pressure. GPR75 is a receptor that is expressed in the heart and blood vessels and has been shown to play a role in the regulation of blood pressure.

Researchers have developed new treatments that target these pathways. For example, soluble epoxide hydrolase inhibitors (SEHIs) are drugs that block the production of 20-HETE, which can help to reduce blood pressure. SEHIs are currently being tested in clinical trials and have shown promising results.

Another area of focus has been on the use of allosteric modifiers of adenosine receptors in the treatment of hypertension. Adenosine receptors are proteins that are expressed on the surface of cells and play a role in the regulation of blood pressure. Allosteric modifiers are drugs that bind to adenosine receptors and can modulate their activity.

Studies have shown that allosteric modifiers of adenosine receptors can help to reduce blood pressure by relaxing blood vessels and improving blood flow. Allosteric modifiers are currently being tested in clinical trials and have shown promising results.

In addition to these new treatments, there are also drugs that affect the nitric oxide-cyclic GMP pathway in hypertension. Nitric oxide is a gas that is produced by the body and plays a role in the regulation of blood pressure. Cyclic GMP is a molecule that is produced by the body and plays a role in the relaxation of blood vessels.

Drugs that affect the nitric oxide-cyclic GMP pathway can help to reduce blood pressure by increasing the production of nitric oxide and by increasing the activity of cyclic GMP. Drugs that affect the nitric oxide-cyclic GMP pathway are currently being tested in clinical trials and have shown promising results.

Relaxin-2 and serelaxin are two hormones that are produced by the body and play a role in the regulation of blood pressure. Relaxin-2 is a peptide that is produced by the brain and has been shown to relax blood vessels and improve blood flow. Serelaxin is a peptide that is produced by the body and has been shown to relax blood vessels and improve blood flow.

Studies have shown that relaxin-2 and serelaxin can help to reduce blood pressure by reducing the activity of the renin-angiotensin-aldosterone system (RAAS) and by improving blood flow. Relaxin-2 and serelaxin are currently being tested in clinical trials and have shown promising results.

In conclusion, hypertension is a common condition that can lead to serious health problems. While there are many treatments available for hypertension, there is still a need for new and more effective therapies. Researchers have made significant progress in understanding the mechanisms underlying hypertension and developing new treatments.

New treatments that target the cytochrome P450, 20-HETE and GPR75 pathway, as well as allosteric modifiers of adenosine receptors, and drugs that affect the nitric oxide-cyclic GMP pathway, are currently being tested in clinical trials and have shown promising results. In addition, relaxin-2 and serelaxin are two hormones that are being tested in clinical trials and have shown promising results.

As research continues, it is likely that new and more effective treatments for hypertension will be developed in the future. These treatments could help to reduce the risk of serious health problems and improve the quality of life for millions of people worldwide.

Dimension: 229 x 152 (mm)
ISBN-13: 9780323910873